AMEX
28.95USD
+0.04 (+0.14%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
100.6M
P/E
—
EPS
—
Beta
3.13
52W range
18.19-37.5
Day range
25.83–29.77
Open
27.80
Prev close
28.91
Volume
43.3K
Avg volume
40.3K
Dividend
0.00
IPO
2024-02-16
https://www.marketbeat.com/instant-alerts/pelthos-therapeutics-q2-earnings-call-highlights-2026-08-14/ · 8/14/2026+0.40
https://www.marketbeat.com/instant-alerts/pelthos-therapeutics-q1-earnings-call-highlights-2026-05-15/ · 5/16/2026+0.80
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
